Research Summary

Dr. Hala Borno is faculty at UCSF and an Associate Professor in the Department of Medicine and Division of Hematology/Oncology and co-Medical Director of the Genitourinary Medical Oncology Clinic at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) at the University of California San Francisco (UCSF). Dr. Borno is a medical oncologist with clinical expertise in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. At HDFCCC, Dr. Borno serves on the executive leadership committee for the Prostate Cancer Program and the Liaison to the Office of Community Engagement. She is also a member of the American Society of Clinical Oncology Social Determinants of Health working group, and GU committee for NRG oncology. She serves as the Vice Chair of the Health Disparities Committee for Alliance for Clinical Trials in Oncology.

Dr. Borno's research program consists of prostate cancer therapeutic development and cancer disparities. She serves as medical oncology co-chair for phase III clinical trials and is the principal investigator for clinical trials conducted at HDFCCC in advanced prostate cancer. Dr. Borno has an extensive research program on the promotion of equity in cancer precision medicine.

She has developed novel recruitment technologies that are clinician and patient facing to promote diversity and inclusion of racial/ethnic minorities in clinical trials. Dr. Borno used human-centered design to develop Trial LibraryTM, a patient facing clinical trial matching tool. Dr. Borno's research has been featured in peer-reviewed journals such JAMA Oncology, Cancer, and Nature. Her work has been covered by national news outlets such as NPR, Washington Post, CBS News, Bloomberg News, and STAT News.

Dr. Borno graduated with honors in biochemistry and received her medical degree from the University of North Carolina at Chapel Hill where she was a Medical Alumni Loyalty Fund Scholar. She completed her internal medicine residency and medical oncology fellowship training at UCSF. She served as chief oncology fellow at UCSF and was a National Institute on Aging T32 research fellow in the Division of Geriatrics.


University of North Carolina at Chapel Hill, B.S., 05/2008, Biochemistry
University of North Carolina at Chapel Hill, M.D., 05/2013, Medicine
University of California, San Francisco, Intern, 06/2014, Internal Medicine
University of California, San Francisco, Resident, 06/2016, Internal Medicine

Honors & Awards

  • 2009
    Foreign Language Area Studies Fellowship
  • 2011-2012
    Furlow Fund Global Health Research Fellowship, University of North Carolina at Chapel Hill
  • 2009-2013
    Medical Alumni Loyalty Fund Scholarship
  • 2013
    Arnold P. Gold Foundation
  • 2013
    Daniel T. Young Peace and Social Justice Award
  • 2017-present
    Geriatrics T32 NIH Grant
  • 2017-present
    Inside Out Accelerator Grant from the Clinical Innovation Center

Selected Publications

  1. Loeb S, Ravenell JE, Gomez SL, Borno HT, Siu K, Sanchez Nolasco T, Byrne N, Wilson G, Griffith DM, Crocker R, Sherman R, Washington SL, Langford AT. The Effect of Racial Concordance on Patient Trust in Online Videos About Prostate Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2023 07 03; 6(7):e2324395.  View on PubMed
  2. Edward Maldonado, Thomas A. Hope, Rahul Raj Aggarwal, Daniel H Kwon, Li Zhang, Kelly Gordon, Barry Tong, Adina Bailey, Vipul Kumar, Ivan de Kouchkovsky, Vadim S Koshkin, Hala Borno, Jonathan Chou, Rohit Bose, Lawrence Fong, Arpita Desai, Terence W. Friedlander, Eric Jay Small. Defining the prevalence of inherited DNA damage repair genetic variants (DDRv) in men with prostate cancer (PCa) detected by PSMA PET. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):e17010-e17010.  View on PubMed
  3. Wang EY, Borno HT, Washington Iii SL, Friedlander T, Zhang S, Trejo E, Van Blarigan EL, Chan JM, Shariff-Marco S, Beatty AL, Kenfield SA. Engaging Men of Diverse Racial and Ethnic Groups With Advanced Prostate Cancer in the Design of an mHealth Diet and Exercise Intervention: Focus Group Study. JMIR Cancer. 2023 Jun 01; 9:e45432.  View on PubMed
  4. Alberto Carretero-González, Daniel Kwon, Nonna Shakhnazaryan, Julian C. Hong, Osama Mohamad, Mary Uan-Sian Feng, Ivan de Kouchkovsky, Hala Borno, Rohit Bose, Jonathan Chou, Arpita Desai, Lawrence Fong, Terence W. Friedlander, Vadim S Koshkin, Felix Y Feng, Rahul Raj Aggarwal, Thomas A. Hope, Eric Jay Small. Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):5032-5032.  View on PubMed
  5. Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma PatientsTreated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. Clin Genitourin Cancer. 2023 May 17.  View on PubMed
  6. Ragavan MV, Borno HT. The costs and inequities of precision medicine for patients with prostate cancer: A call to action. Urol Oncol. 2023 09; 41(9):369-375.  View on PubMed
  7. Terence W. Friedlander, Hala T. Borno. In Regard to Lastname et al. International Journal of Radiation Oncology • Biology • Physics. 2023 May 1; 116(1):14-15.  View on PubMed
  8. Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. Front Oncol. 2023; 13:1161089.  View on PubMed
  9. Kenfield SA, Van Blarigan EL, Graff RE, Borno HT, Macaire G, Chan JM. Nutrition Guidance for Patients on Androgen Deprivation Therapy. Eur Urol Focus. 2023 May; 9(3):427-430.  View on PubMed
  10. Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, Blau S, Bodin BE, Borno HT, Castellano C, Choi H, Deeken J, Desai A, Edwin N, Feldman LE, Flora DB, Friese CR, Galsky MD, Gonzalez CJ, Grivas P, Gupta S, Haynam M, Heilman H, Hershman DL, Hwang C, Jani C, Jhawar SR, Joshi M, Kaklamani V, Klein EJ, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Labaki C, Lammers PE, Lathrop KI, Lewis MA, Li X, de Lima Lopes G, Lyman GH, Makower DF, Mansoor AH, Markham MJ, Mashru SH, McKay RR, Messing I, Mico V, Nadkarni R, Namburi S, Nguyen RH, Nonato TK, O'Connor TL, Panagiotou OA, Park K, Patel JM, Patel KG, Peppercorn J, Polimera H, Puc M, Rao YJ, Razavi P, Reid SA, Riess JW, Rivera DR, Robson M, Rose SJ, Russ AD, Schapira L, Shah PK, Shanahan MK, Shapiro LC, Smits M, Stover DG, Streckfuss M, Tachiki L, Thompson MA, Tolaney SM, Weissmann LB, Wilson G, Wotman MT, Wulff-Burchfield EM, Mishra S, French B, Warner JL, Lustberg MB, Accordino MK, Shah DP. Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. medRxiv. 2023 Mar 10.  View on PubMed
  11. Kevin R Reyes, Li Zhang, Xiaolin Zhu, Tanya Jindal, Prianka Deshmukh, Ivan de Kouchkovsky, Vipul Kumar, Edward Maldonado, Daniel H Kwon, Emily Chan, Sima P. Porten, Hala Borno, Rohit Bose, Arpita Desai, Rahul Raj Aggarwal, Eric Jay Small, Lawrence Fong, Jonathan Chou, Terence W. Friedlander, Vadim S Koshkin. Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs). Journal of Clinical Oncology. 2023 Feb 20; 41(6_suppl):532-532.  View on PubMed
  12. Tanya Jindal, Xiaolin Zhu, Li Zhang, Kevin R Reyes, Prianka Deshmukh, Ivan de Kouchkovsky, Vipul Kumar, Edward Maldonado, Chase Shipp, Daniel H Kwon, Hala Borno, Rohit Bose, Arpita Desai, Rahul Raj Aggarwal, Sima P. Porten, Eric Jay Small, Lawrence Fong, Jonathan Chou, Terence W. Friedlander, Vadim S Koshkin. Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB). Journal of Clinical Oncology. 2023 Feb 20; 41(6_suppl):534-534.  View on PubMed
  13. Annelise Thorn, Kelly Gordon, Barry Tong, Daniel H Kwon, Mallika Sachdev Dhawan, Hala Borno, Rahul Raj Aggarwal, Eric Jay Small, Amie Blanco. Disparities in germline testing by race/ethnicity and preferred language in patients with prostate cancer. Journal of Clinical Oncology. 2023 Feb 20; 41(6_suppl):112-112.  View on PubMed
  14. Medina SP, Zhang S, Nieves E, Dornsife DL, Johnson R, Spicer D, Borno HT. Experiences of a Multiethnic Cohort of Patients Enrolled in a Financial Reimbursement Program for Cancer Clinical Trials. JCO Oncol Pract. 2023 05; 19(5):e801-e810.  View on PubMed
  15. Deville C, Borno HT. Declining Representation and Reporting of Racial and Ethnic Minority Patients in Prostate Cancer Clinical Trials Despite Persistent Health Disparities-Where Progress Confronts Limitations. JAMA Oncol. 2023 02 01; 9(2):175-177.  View on PubMed
  16. Kwon DH, Gordon KM, Tong B, Borno HT, Beigh M, Fattah D, Schleicher A, Aggarwal RR, Blanco AM, Small EJ, Dhawan M. Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer. JCO Oncol Pract. 2023 05; 19(5):e773-e783.  View on PubMed
  17. Langlais CS, Chen YH, Van Blarigan EL, Chan JM, Ryan CJ, Zhang L, Borno HT, Newton RU, Luke A, Bang AS, Panchal N, Tenggara I, Schultz B, Lavaki E, Pinto N, Aggarwal R, Friedlander T, Koshkin VS, Harzstark AL, Small EJ, Kenfield SA. Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention. Urol Oncol. 2023 03; 41(3):146.e1-146.e11.  View on PubMed
  18. Ragavan MV, Legaspi N, LaLanne A, Hong JC, Small EJ, Borno HT. Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic. JAMA Oncol. 2022 12 01; 8(12):1849-1851.  View on PubMed
  19. Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. Urol Oncol. 2023 03; 41(3):145.e7-145.e15.  View on PubMed
  20. Ragavan MV, Mora RV, Winder K, Incudine A, Cunningham R, Stivers T, Borno HT. Impact of a Comprehensive Financial Resource on Financial Toxicity in a National, Multiethnic Sample of Adult, Adolescent/Young Adult, and Pediatric Patients With Cancer. JCO Oncol Pract. 2023 02; 19(2):e286-e297.  View on PubMed

Go to UCSF Profiles, powered by CTSI